Phase III, randomized, controlled, multicenter, open-label trial (DESTINY-Breast-02) HER2-positive, previously received trastuzumab-emtansine, unresectable or metastatic breast can

24 Jun

Soft Tissue Sarcoma

New Protocol: Nivolumab and Trabectedin in Advanced Soft Tissue Sarcoma

Prospective, explorative, two-group, non-randomized, phase II trial (NITraSarc) Advanced, previously treated lipo-leiomyosarcoma (Group A: GA) (n=43) and non-L-sarcomas (Group B:

20 Sep

Mantle cell lymphoma

New Protocol: Ibrutinib with Rituximab and Bendamustine for Mantle Cell Lymphoma

International, randomized, double-blind, phase 3 trial (SHINE) 65 years of age or older mantle cell lymphoma Untreated, stage II to IV disease Ibrutinib (N:261) or placebo (N:262),

14 Apr

Melanoma

New Indication: Perioperative Pembrolizumab in Melanoma

Open-label, phase 2 study Treatment naïve resectable sage IIIB-IVC metastatic melanoma (cutaneous, acral, or mucosal) Pembrolizumab: Neoadjuvant-adjuvant (n=154) vs. Adjuvant (n=1

20 Sep

Non-Small Cell Lung Cancer

New Indication: Neoadjuvant Nivolumab for NSCLC

Open-label, phase 3 trial Stage IB to IIIA resectable NSCLC Three cycles neoadjuvant treatment Nivolumab plus platinum-based chemotherapy (n=176) or platinum-based chemotherapy (n=

20 Aug

Colorectal Cancer

New Indication: Avelumab for MSI-High Metastatic Colorectal Cancer

A Phase II, Randomized, Open-label, multicenter trial Progression under first-line treatment (except for immunotherapy) of dMMR/MSI metastatic colorectal cancer Avelumab (n=65) vs

20 May

Follicular Lymphoma

New Reference: SubQ Rituximab for Follicular Lymphoma

Randomized, open-label phase 3 trial (LYSA) Previously untreated low-burden Follicular lymphoma SOC (n=102) vs. Rituximab sc (n=100)

20 May

Chronic Lymphocytic Leukemia

New Reference: Ibrutinib and Rituximab for CLL

Phase III, randomized,controlled, multicenter, open-label trial (FLAIR) Treatment naive CLL–small lymphocytic lymphoma (SLL) İbrutinib + Rituximab (n=386) vs. FCR (n=385)

20 Sep

Gastrointestinal Stromal Tumor

New Drug: Ripretinib for Advanced GIST

Randomized, open-label, international, multicenter phase III study Advanced GIST who progressed on or were intolerant to first-line treatment with imatinib Ripretinib 150 mg (n = 2

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries